Source: Healio News
Although chimeric antigen receptor T-cell therapy is approved for treatment of multiple myeloma, commercially available products are limited to patients who received at least four prior lines of therapy.
Given its impressive activity among heavily pretreated patients, commercial sponsors aim to test CAR-T as earlier therapy in clinical trials, while other researchers are developing novel CAR-T constructs with a wider array of targets for the disease.
It is never too early to consider the use of CAR T cells for multiple myeloma, according to Nina Shah, MD, professor of clinical medicine at